Lung Cancer
CA266-0002:ROSETTA Lung-202: A Randomized, Double-Blind, Phase 3 Study of Pumitamig Monotherapy Compared to Pembrolizumab as First-line Treatment in Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with PD-L1 >= 50%.
- Details
ClinicalTrials.gov ID:
NCT07361510
Diagnosis Type:
NA
USOR Number:
- Address
,
P: